Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Obsessive-Compulsive Disorder Set (abstract data type)

1 paper

Obsessive-Compulsive Disorder

Based on 12 papers

Researchers are testing several treatment approaches for obsessive‑compulsive disorder (OCD). These include traditional psychotherapies, ketamine (a fast-acting medicine), and psychedelic-assisted therapies (where a mind‑altering drug is given together with psychological support). Some early reports and small studies suggest benefits, but the strongest proof so far is for depression and addiction, not OCD. Many psychedelic and ketamine studies are small or early‑stage and need larger, careful trials. What patients and clinicians should know is this: no psychedelic medicine is officially approved yet. How the drug is given, the safety checks, and the therapy before and after a drug session matter a lot. Research also has limits: many trials have few participants, people of color are often left out, and the growing business around these drugs raises extra scientific and ethical questions.

Key findings

  • No psychedelic medicine has been approved for psychiatric disorders yet. 15078 15085
  • A large review of psychotherapies found a pooled response rate for OCD of about 38% (response means roughly a 50% symptom drop in trials). 12851
  • A retrospective online survey (people reporting their own past use) found that participants said only classic psychedelics (the traditional serotonin‑acting drugs) reduced their OCD symptoms. 15088
  • In that survey, people who felt stronger short‑term effects during a psychedelic trip also reported bigger drops in OCD symptoms, and stronger effects were linked to higher doses. 15088
  • Ketamine and a nasal form called esketamine have shown rapid benefits in some studies, and have been reported to help several conditions including OCD in early research. 10149
  • Psychodynamic (talking) therapy shows little evidence of benefit for OCD in the review of outcome studies. 13302
  • Good preparation before drug‑assisted therapy sessions (screening, setting expectations, and building trust) is widely agreed to be important for safety and probably for outcomes. 15065
  • The best current clinical evidence for psychedelic therapy is for major depression, treatment‑resistant depression, and some addictions; evidence for anxiety disorders and OCD is still emerging and less certain. 15053 15091
  • People of color have been greatly underrepresented in psychedelic‑assisted psychotherapy studies, so study results may not apply to all ethnic or cultural groups. 15095 15092

Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review

Sascha Thal, Michelle Wieberneit, Jason M. Sharbanee, Petra Skeffington, Paris Baker, Raimondo Bruno, et al.
Journal of Psychopharmacology Summary & key facts 2022 23 citations

The authors reviewed 83 papers and guides about how therapists prepare people for substance-assisted psychotherapy — therapy that uses drugs like psilocybin, LSD, MDMA, or ketamine together with psychological support. They found clear agreement that good preparation before a drug session is important for safety and for helping people get…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ibogaine Ketamine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.